Sabinsa Corporation participated in the Nutraceuticals Europe Summit and Expo held in Barcelona between 8th & 9th Mar, 2023. Sabinsa had fantastic interactions with business prospects at the expo whilst showcasing its range of innovative ingredients.

The show featured a presentation on "Curcumin C3 Reduct® “Integrating Curcumin C3 Reduct® in new product development" delivered by Dr. Umar Jan, President, Sabinsa European Operations. At the seminar, Dr. Umar underscored the significance of C3 Reduct® which has been scientifically shown to boost organ health and deliver a range of other targeted functionalities. Curcumin C3 Reduct ® (Tetrahydrocurcuminoids) is the only Curcumin metabolite product that is approved by EFSA. It is directly and easily assimilated into the body as an active metabolite. At 140mg/ day, C3 Reduct® delivers functionality without the need for high dosages or added synthetic ingredients. C3 Reduct is EFSA approved Curcumin product as per the EU commission implementing regulation 2022/961.

The session was highly interactive and engaging, with Dr. Umar addressing the audience's queries with relevant details leading to an overall positive response from the attendees.

We sincerely appreciate the attendees for taking the time to learn about our ingredients.

® Registered trademark of Sabinsa Corporation, USA
™ Registered trademark of Sabinsa Corporation, USA